28 June 2024
28 June 2024
Ohtuvayre improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.
Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance. Daniel J. Herron, a life sciences specialist, explains why one of the key factors in improving participant involvement is document readability.
The recent raise will bring the biotech accelerator Curie.Bio’s total funds raised to nearly $1bn since it launched back in February 2023.
Biotechs with AI-led drug pipelines appear to be enjoying higher investment attraction.
2seventy bio’s deal with Novo Nordisk also includes the rights to its MegaTAL in vivo gene editing technology.
The deal will bolster AbbVie's inflammatory disease portfolio with anti-TREM1 antibody CEL383.
As the funding market evolves, there is greater emphasis on companies having commercial plans and using AI for drug discovery.
Ohtuvaye is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
